---
schema_version: "secwatch.filing_event.v1"
accession: "0001576280-22-000118"
form_type: "8-K"
ticker: "GH"
cik: "0001576280"
company_name: "Guardant Health, Inc."
filed_at: "2022-12-15T23:59:59+00:00"
generated_at: "2026-06-21T04:08:22.679046+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Guardant Health ECLIPSE blood test shows 83% sensitivity for colorectal cancer in 20,000+ patient study

## Summary
- ECLIPSE study: 83% sensitivity for CRC detection, 90% specificity vs. negative colonoscopy.
- Advanced adenoma sensitivity at 13%; cfDNA-only test outperformed cfDNA+protein version.
- Plans PMA submission to FDA in Q1 2023; results exceed CMS reimbursement criteria.
- Blood test completion rate 90% vs. 43-66% for stool tests; aims to address 49M unscreened adults.
- Guardant expands test to other cancers including lung cancer; co-CEO cites breakthrough in blood-based screening.

## SEC filing metadata
- accession: 0001576280-22-000118
- form_type: 8-K
- ticker: GH
- cik: 0001576280
- company_name: Guardant Health, Inc.
- filed_at: 2022-12-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576280/000157628022000118/0001576280-22-000118-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576280/000157628022000118/gh-20221215.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001576280-22-000118
- JSON: https://secwatch.observer/filing/0001576280-22-000118.json
- Plain text: https://secwatch.observer/filing/0001576280-22-000118.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.